You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePonatinib
Accession NumberDB08901
TypeSmall Molecule
GroupsApproved
DescriptionPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Structure
Thumb
Synonyms
AP 24534
AP24534
Ponatinibum
External Identifiers
  • AP24534
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IclusigTablet15 mgOralAriad Pharmaceuticals Inc2015-08-21Not applicableCanada
IclusigTablet, film coated15 mg/1OralARIAD Pharmaceuticals, Inc.2012-12-14Not applicableUs
IclusigTablet45 mgOralAriad Pharmaceuticals Inc2016-01-07Not applicableCanada
IclusigTablet, film coated30 mg/1OralARIAD Pharmaceuticals, Inc.2015-04-22Not applicableUs
IclusigTablet, film coated45 mg/1OralARIAD Pharmaceuticals, Inc.2012-12-14Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ponatinib Hydrochloride
Thumb
  • InChI Key: BWTNNZPNKQIADY-UHFFFAOYSA-N
  • Monoisotopic Mass: 568.19652187
  • Average Mass: 569.02
DBSALT000142
Categories
UNII4340891KFS
CAS number943319-70-8
WeightAverage: 532.5595
Monoisotopic: 532.219844131
Chemical FormulaC29H27F3N6O
InChI KeyPHXJVRSECIGDHY-UHFFFAOYSA-N
InChI
InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
IUPAC Name
3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
SMILES
CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1
Pharmacology
IndicationPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionPonatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. This protein arises from the fused Bcr and Abl gene- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in tumour size expressing native or T315I mutant BCR-ABL have been observed in rats.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tyrosine-protein kinase ABL1Proteinyes
inhibitor
HumanP00519 details
Breakpoint cluster region proteinProteinyes
inhibitor
HumanP11274 details
Mast/stem cell growth factor receptor KitProteinunknown
inhibitor
HumanP10721 details
Proto-oncogene tyrosine-protein kinase receptor RetProteinunknown
inhibitor
HumanP07949 details
Angiopoietin-1 receptorProteinunknown
inhibitor
HumanQ02763 details
Receptor-type tyrosine-protein kinase FLT3Proteinunknown
inhibitor
HumanP36888 details
Fibroblast growth factor receptor 1Proteinunknown
inhibitor
HumanP11362 details
Fibroblast growth factor receptor 2Proteinunknown
inhibitor
HumanP21802 details
Fibroblast growth factor receptor 3Proteinunknown
inhibitor
HumanP22607 details
Fibroblast growth factor receptor 4Proteinunknown
inhibitor
HumanP22455 details
Tyrosine-protein kinase LckProteinunknown
inhibitor
HumanP06239 details
Proto-oncogene tyrosine-protein kinase SrcProteinunknown
inhibitor
HumanP12931 details
Tyrosine-protein kinase LynProteinunknown
inhibitor
HumanP07948 details
Vascular endothelial growth factor receptor 2Proteinunknown
inhibitor
HumanP35968 details
Platelet-derived growth factor receptor alphaProteinunknown
inhibitor
HumanP16234 details
Related Articles
AbsorptionThe absolute bioavailability of ponatinib is unknown. Peak concentrations of ponatinib are observed within 6 hours after Iclusig oral administration. Food does not affect absorption of food. The aqueous solubility of ponatinib is pH dependent, with higher pH resulting in lower solubility. When 45 mg of ponatinib is given to cancer patients, the pharmacokinetic parameters are as follows: Cmax = 73 ng/mL; AUC = 1253 ng•hr/mL;
Volume of distribution

After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the steady state volume of distribution is 1223 L. Ponatinib is a weak substrate for P-gp and ABCG2.

Protein binding> 99% bound to plasma proteins.
Metabolism

At least 64% of a ponatinib dose undergoes phase I and phase II metabolism. CYP3A4 and to a lesser extent CYP2C8, CYP2D6 and CYP3A5 are involved in the phase I metabolism of ponatinib in vitro. Ponatinib is also metabolized by esterases and/or amidases.

Route of eliminationPonatinib is mainly eliminated via feces. Following a single oral dose of [14C]-labeled ponatinib, approximately 87% of the radioactive dose is recovered in the feces and approximately 5% in the urine.
Half lifeAfter oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).
ClearanceNot Available
ToxicityThe most common non-hematologic adverse reactions (≥ 20%) were hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia. Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Ponatinib can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ponatinib.Approved
AcetaminophenThe serum concentration of Ponatinib can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ponatinib.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ponatinib.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ponatinib.Approved
AlbendazoleThe serum concentration of Ponatinib can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Ponatinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Ponatinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Ponatinib can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ponatinib.Approved, Investigational
AmantadineThe serum concentration of Ponatinib can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ponatinib.Approved, Investigational
Aminohippuric acidThe serum concentration of Ponatinib can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Ponatinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Ponatinib can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Ponatinib can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Ponatinib.Approved
AmprenavirThe serum concentration of Ponatinib can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Ponatinib can be increased when it is combined with Amsacrine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Ponatinib.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ponatinib.Approved
AprepitantThe serum concentration of Ponatinib can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ponatinib.Approved, Investigational
ArtemetherThe metabolism of Ponatinib can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Ponatinib can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Ponatinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Ponatinib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Ponatinib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Ponatinib can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ponatinib.Approved, Investigational
AzelastineThe serum concentration of Ponatinib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Ponatinib can be increased when it is combined with Azithromycin.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Ponatinib.Investigational
BenzocaineThe serum concentration of Ponatinib can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Ponatinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ponatinib.Approved, Vet Approved
BetaxololThe metabolism of Ponatinib can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ponatinib.Approved, Investigational
BexaroteneThe serum concentration of Ponatinib can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Ponatinib can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Ponatinib can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Ponatinib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ponatinib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ponatinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib.Approved
BromocriptineThe serum concentration of Ponatinib can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Ponatinib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Ponatinib can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Ponatinib can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ponatinib.Approved
CaffeineThe serum concentration of Ponatinib can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ponatinib.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.Approved
CandesartanThe serum concentration of Ponatinib can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Ponatinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Ponatinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ponatinib.Approved
CarvedilolThe serum concentration of Ponatinib can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Ponatinib can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Ponatinib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ponatinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ponatinib.Withdrawn
ChloroquineThe serum concentration of Ponatinib can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Ponatinib can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Ponatinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Ponatinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Ponatinib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Ponatinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidPonatinib may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilazaprilThe serum concentration of Ponatinib can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Ponatinib can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Ponatinib can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ponatinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ponatinib.Approved
CitalopramThe serum concentration of Ponatinib can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Ponatinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Ponatinib can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ponatinib.Approved, Illicit
ClofazimineThe serum concentration of Ponatinib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ponatinib.Approved, Investigational
ClomipramineThe serum concentration of Ponatinib can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ponatinib.Approved
ClopidogrelThe metabolism of Ponatinib can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Ponatinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Ponatinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Ponatinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ponatinib.Approved
CocaineThe metabolism of Ponatinib can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ponatinib.Approved
ColforsinThe serum concentration of Ponatinib can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Ponatinib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ponatinib.Approved
CrizotinibThe metabolism of Ponatinib can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ponatinib.Approved, Investigational
CyclosporineThe metabolism of Ponatinib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ponatinib.Approved
DabrafenibThe serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Ponatinib can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Ponatinib can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ponatinib.Approved
DarifenacinThe metabolism of Ponatinib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ponatinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ponatinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Ponatinib can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ponatinib.Approved
DeferasiroxThe serum concentration of Ponatinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ponatinib can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Ponatinib can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ponatinib.Approved
DesloratadineThe serum concentration of Ponatinib can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Ponatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Ponatinib can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ponatinib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Ponatinib can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ponatinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ponatinib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Ponatinib.Approved
DihydroergotamineThe metabolism of Ponatinib can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ponatinib.Illicit
DiltiazemThe metabolism of Ponatinib can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Ponatinib can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Ponatinib can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ponatinib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ponatinib.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Ponatinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Ponatinib can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ponatinib.Approved, Investigational
DoxorubicinThe serum concentration of Ponatinib can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Ponatinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Ponatinib can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Ponatinib can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Ponatinib can be decreased when combined with Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ponatinib.Approved
EfavirenzThe serum concentration of Ponatinib can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Ponatinib can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ponatinib.Approved, Investigational
EliglustatThe metabolism of Ponatinib can be decreased when combined with Eliglustat.Approved
EltrombopagThe serum concentration of Ponatinib can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Ponatinib can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Ponatinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ponatinib.Approved, Investigational
ErgonovineThe serum concentration of Ponatinib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ponatinib can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ponatinib.Approved, Investigational
ErythromycinThe metabolism of Ponatinib can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ponatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ponatinib.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Ponatinib can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Ponatinib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Ponatinib can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ponatinib.Approved
EtoposideThe serum concentration of Ponatinib can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Ponatinib can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ponatinib.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ponatinib.Approved
FelodipineThe serum concentration of Ponatinib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Ponatinib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ponatinib.Approved
FexofenadineThe serum concentration of Ponatinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Ponatinib can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe metabolism of Ponatinib can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Ponatinib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Ponatinib can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Ponatinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Ponatinib can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ponatinib.Approved
FluvoxamineThe metabolism of Ponatinib can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ponatinib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ponatinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ponatinib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ponatinib can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Ponatinib can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ponatinib.Approved
GemfibrozilThe metabolism of Ponatinib can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Ponatinib can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Ponatinib can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Ponatinib can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Ponatinib can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ponatinib.Approved
GrepafloxacinThe serum concentration of Ponatinib can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Ponatinib can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Ponatinib can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ponatinib.Approved
IdelalisibThe serum concentration of Ponatinib can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Ponatinib can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Ponatinib can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ponatinib.Approved
IndinavirThe serum concentration of Ponatinib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Ponatinib can be increased when it is combined with Indomethacin.Approved, Investigational
IrbesartanThe metabolism of Ponatinib can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ponatinib.Approved, Investigational
IsavuconazoniumThe metabolism of Ponatinib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Ponatinib can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Ponatinib can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ponatinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ponatinib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ponatinib can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Ponatinib can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ponatinib.Approved
KetoconazoleThe serum concentration of Ponatinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ponatinib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ponatinib.Approved, Investigational
LansoprazoleThe serum concentration of Ponatinib can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Ponatinib can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ponatinib.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ponatinib.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ponatinib.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ponatinib.Approved, Investigational
LevofloxacinThe serum concentration of Ponatinib can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ponatinib.Approved
LevothyroxineThe serum concentration of Ponatinib can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Ponatinib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ponatinib.Approved
LiothyronineThe serum concentration of Ponatinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Ponatinib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Ponatinib can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Ponatinib can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Ponatinib can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Ponatinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Ponatinib can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Ponatinib can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Ponatinib can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Ponatinib can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Ponatinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ponatinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ponatinib can be decreased when combined with Lumefantrine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ponatinib.Approved, Investigational
MaprotilineThe serum concentration of Ponatinib can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Ponatinib can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Ponatinib can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Ponatinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Ponatinib can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ponatinib.Withdrawn
MethadoneThe serum concentration of Ponatinib can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ponatinib.Approved
MethotrimeprazineThe metabolism of Ponatinib can be decreased when combined with Methotrimeprazine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ponatinib.Approved, Vet Approved
MetoprololThe serum concentration of Ponatinib can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Ponatinib can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Ponatinib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ponatinib can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Ponatinib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ponatinib.Approved
MitomycinThe serum concentration of Ponatinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Ponatinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Ponatinib can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Ponatinib can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Ponatinib can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ponatinib.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Ponatinib.Approved
NafcillinThe serum concentration of Ponatinib can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ponatinib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ponatinib.Approved, Vet Approved
NaltrexoneThe serum concentration of Ponatinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Ponatinib can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Ponatinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ponatinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Ponatinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Ponatinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Ponatinib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Ponatinib can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Ponatinib can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Ponatinib can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ponatinib.Approved
NisoldipineThe serum concentration of Ponatinib can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Ponatinib can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Ponatinib can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ponatinib.Approved
NorethisteroneThe serum concentration of Ponatinib can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ponatinib.Approved, Investigational
OlaparibThe metabolism of Ponatinib can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ponatinib.Approved
OmeprazoleThe serum concentration of Ponatinib can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Ponatinib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Ponatinib.Approved
P-NitrophenolThe serum concentration of Ponatinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ponatinib.Approved, Vet Approved
PalbociclibThe serum concentration of Ponatinib can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Ponatinib can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Ponatinib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Ponatinib can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe metabolism of Ponatinib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ponatinib.Approved
Peginterferon alfa-2bThe serum concentration of Ponatinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Ponatinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Ponatinib can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Ponatinib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Ponatinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Ponatinib can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Ponatinib can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ponatinib.Approved
Platelet Activating FactorThe serum concentration of Ponatinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Ponatinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Ponatinib can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Ponatinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ponatinib.Approved, Vet Approved
PrednisoneThe serum concentration of Ponatinib can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Ponatinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Ponatinib can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Ponatinib can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Ponatinib can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Ponatinib can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Ponatinib can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Ponatinib can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Ponatinib can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ponatinib.Approved
QuercetinThe serum concentration of Ponatinib can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ponatinib.Approved
QuinacrineThe serum concentration of Ponatinib can be increased when it is combined with Quinacrine.Approved
QuinidineThe metabolism of Ponatinib can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Ponatinib can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Ponatinib can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Ponatinib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ponatinib.Approved, Investigational
ReboxetineThe serum concentration of Ponatinib can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Ponatinib can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Ponatinib can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Ponatinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ponatinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ponatinib can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ponatinib.Approved, Investigational
RilpivirineThe serum concentration of Ponatinib can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ponatinib.Approved, Investigational
RitonavirThe serum concentration of Ponatinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ponatinib.Approved
RolapitantThe serum concentration of Ponatinib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ponatinib.Approved, Investigational
RopiniroleThe metabolism of Ponatinib can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Ponatinib can be decreased when combined with Rosiglitazone.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ponatinib.Approved, Vet Approved
SaquinavirThe serum concentration of Ponatinib can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Ponatinib can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Ponatinib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Ponatinib can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ponatinib.Approved
SertralineThe serum concentration of Ponatinib can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Ponatinib can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ponatinib.Approved
SiltuximabThe serum concentration of Ponatinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ponatinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Ponatinib can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Ponatinib can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ponatinib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ponatinib.Approved
SorafenibThe serum concentration of Ponatinib can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ponatinib.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ponatinib.Experimental
SpironolactoneThe serum concentration of Ponatinib can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Ponatinib can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Ponatinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Ponatinib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Ponatinib can be decreased when it is combined with Streptozocin.Approved
SulfamethoxazoleThe metabolism of Ponatinib can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Ponatinib can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Ponatinib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Ponatinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Ponatinib can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Ponatinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Ponatinib can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Ponatinib can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Ponatinib can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ponatinib.Approved
TelaprevirThe serum concentration of Ponatinib can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Ponatinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Ponatinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Ponatinib can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Ponatinib can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Ponatinib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Ponatinib can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Ponatinib can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Ponatinib can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ponatinib can be increased when it is combined with Testosterone.Approved, Investigational
ThioridazineThe metabolism of Ponatinib can be decreased when combined with Thioridazine.Approved
TicagrelorThe serum concentration of Ponatinib can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ponatinib can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Ponatinib.Approved
TipranavirThe metabolism of Ponatinib can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Ponatinib can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Ponatinib can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ponatinib.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ponatinib.Approved, Investigational
TranylcypromineThe metabolism of Ponatinib can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ponatinib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ponatinib.Approved
TrazodoneThe serum concentration of Ponatinib can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Ponatinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Ponatinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Ponatinib can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Ponatinib can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Ponatinib can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ponatinib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ponatinib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ponatinib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ponatinib.Approved
VenlafaxineThe metabolism of Ponatinib can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ponatinib can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Ponatinib can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ponatinib.Approved, Investigational
VincristineThe serum concentration of Ponatinib can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Ponatinib can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ponatinib.Approved
VoriconazoleThe serum concentration of Ponatinib can be increased when it is combined with Voriconazole.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ponatinib.Approved
ZimelidineThe serum concentration of Ponatinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ponatinib can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Reddy EP, Aggarwal AK: The ins and outs of bcr-abl inhibition. Genes Cancer. 2012 May;3(5-6):447-54. doi: 10.1177/1947601912462126. [PubMed:23226582 ]
External Links
ATC CodesL01XE24
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (295 KB)
MSDSDownload (98 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9444
Caco-2 permeable-0.5985
P-glycoprotein substrateSubstrate0.7205
P-glycoprotein inhibitor IInhibitor0.8197
P-glycoprotein inhibitor IIInhibitor0.9125
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8612
CYP450 2D6 substrateNon-substrate0.7047
CYP450 3A4 substrateSubstrate0.7636
CYP450 1A2 substrateNon-inhibitor0.8592
CYP450 2C9 inhibitorNon-inhibitor0.6804
CYP450 2D6 inhibitorNon-inhibitor0.764
CYP450 2C19 inhibitorInhibitor0.5563
CYP450 3A4 inhibitorNon-inhibitor0.5613
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6686
Ames testNon AMES toxic0.5331
CarcinogenicityNon-carcinogens0.8254
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8377 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8253
hERG inhibition (predictor II)Inhibitor0.7493
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral15 mg
TabletOral45 mg
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral45 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8114874 No2006-12-222026-12-22Us
US9029533 No2006-12-222026-12-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
pKa2.77 and 7.8 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00295 mg/mLALOGPS
logP3.94ALOGPS
logP4.97ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.36ChemAxon
pKa (Strongest Basic)8.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area65.77 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity152.63 m3·mol-1ChemAxon
Polarizability55.69 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-phenylbenzamides. These are benzamides that are N-linked to a phenyl group via the carboxamide group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzamides
Direct ParentN-phenylbenzamides
Alternative Parents
Substituents
  • N-phenylbenzamide
  • N-arylamide
  • Benzoic acid or derivatives
  • Phenylmethylamine
  • Benzylamine
  • Benzoyl
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Toluene
  • Pyridazine
  • Piperazine
  • N-substituted imidazole
  • 1,4-diazinane
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
References
  1. Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T: Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8. [PubMed:23409026 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rho guanyl-nucleotide exchange factor activity
Specific Function:
GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.
Gene Name:
BCR
Uniprot ID:
P11274
Molecular Weight:
142818.07 Da
References
  1. Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T: Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8. [PubMed:23409026 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P: Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013 Sep;98(9):1450-7. doi: 10.3324/haematol.2012.079202. Epub 2013 Mar 28. [PubMed:23539538 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during in...
Gene Name:
RET
Uniprot ID:
P07949
Molecular Weight:
124317.465 Da
References
  1. De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M: Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22. [PubMed:23526464 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from ...
Gene Name:
TEK
Uniprot ID:
Q02763
Molecular Weight:
125829.005 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or...
Gene Name:
FLT3
Uniprot ID:
P36888
Molecular Weight:
112902.51 Da
References
  1. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18;121(16):3165-71. doi: 10.1182/blood-2012-07-442871. Epub 2013 Feb 21. [PubMed:23430109 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (...
Gene Name:
FGFR1
Uniprot ID:
P11362
Molecular Weight:
91866.935 Da
References
  1. Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, Silva J, Cowell J, Hao Z: Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep. 2013 Jun;29(6):2181-90. doi: 10.3892/or.2013.2386. Epub 2013 Apr 4. [PubMed:23563700 ]
  2. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an...
Gene Name:
FGFR2
Uniprot ID:
P21802
Molecular Weight:
92024.29 Da
References
  1. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineraliz...
Gene Name:
FGFR3
Uniprot ID:
P22607
Molecular Weight:
87708.905 Da
References
  1. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in...
Gene Name:
FGFR4
Uniprot ID:
P22455
Molecular Weight:
87953.535 Da
References
  1. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sh2 domain binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antig...
Gene Name:
LCK
Uniprot ID:
P06239
Molecular Weight:
58000.15 Da
References
  1. Gushwa NN, Kang S, Chen J, Taunton J: Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors. J Am Chem Soc. 2012 Dec 19;134(50):20214-7. doi: 10.1021/ja310659j. Epub 2012 Dec 4. [PubMed:23190395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sh3/sh2 adaptor activity
Specific Function:
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including...
Gene Name:
SRC
Uniprot ID:
P12931
Molecular Weight:
59834.295 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Receptor signaling protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending ...
Gene Name:
LYN
Uniprot ID:
P07948
Molecular Weight:
58573.595 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:
KDR
Uniprot ID:
P35968
Molecular Weight:
151525.555 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for...
Gene Name:
PDGFRA
Uniprot ID:
P16234
Molecular Weight:
122668.46 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
Comments
comments powered by Disqus
Drug created on June 08, 2013 16:03 / Updated on December 04, 2016 02:45